http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
박세광,김형표 ( Se Kwang Park,Hyoung Pyo Kim ) 한국센서학회 1992 센서학회지 Vol.1 No.1
A constant temperature type of flow sensor using a solid state micromachining technology was developed for measuring the velocity of gas or liquid. It was designed to detect only the heat convection related to flow velocity. Other heat transfer terms and common mode interferences are canceled by differentiating both reference and exposed flow sensor. It employs the principle that the change of current through the sensing element can be used to measure the flow velocity. An experimental study of the behavior on this flow sensor was performed in a narrow tube(diameter : 8mm) for city water. The relation between power consumption of the flow sensor and square-root of flow velocity is almost linear in the low velocity range(0-200 cm/sec).
박세광,최재건 경북대학교 센서기술연구소 1990 센서技術學術大會論文集 Vol.1 No.1
The theory, design and preliminary test results of a new constant resistance type flow velocity / flow rate sensor are presented. The interface circuit for a flow velocity / flow rate sensor which converts the error signal from sensing element and feedbacks to the sensor is described. Main problems of previous flow velocity / flow rate sensors are: 1)it is difficult to measure flow velocity when the temperature of fluid changes, 2)fabrication process is complicated, and 3)a measurement isn't easy when the temperature of fluid is higher than that of chip. These defects result in difficulty of commercialization of the solid state flow sensor. In this paper, a new flow sensor was designed only with thin film resistor and OP-Amps, which can be fabricated on one chip using solid state technology. It Is not only simpler than previous sensors in the aspect of production process, but also can measure the flow velocity with no relation of fluid temperature or temperature change.
B형 간염 바이러스 감염에 대한 항바이러스 치료를 위한 새로운 표적과 분석 기법
박세광 인제대학교 백병원 2002 仁濟醫學 Vol.23 No.5
There are presently only two licensed therapies for treating liver disease caused by infection with the hepatitis B virus (HBV). These are interferon-alpha and lamivudine. Neither agent was specifically developed as an antiviral compound for treating patients infected with HBV. Both therapies are limited in the clinic by a low response rate and in the case of lamivudine, selection of drug-resistant mutants, whilst troublesome side effects limit the use of interferon-alpha. Several promising nucleoside/nucleotide analogues are undergoing clinical trials, including adefovir dipivoxil and entecavir, both of which appear to be active against lamivudine-resistant HBV. In addition to these nucleoside/nucleotide analogues, it will be important to develop new agents with different modes of action, which can be added to the antiviral cocktails that will be required to adequately suppress and hopefully eliminate HBV replication.